Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis.

Martin-Martin LS, Giovannangeli F, Bizzi E, Massafra U, Ballanti E, Cassol M, Migliore A.

Drug Des Devel Ther. 2017 Mar 29;11:985-994. doi: 10.2147/DDDT.S118298. eCollection 2017.

2.

Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Croft M, Siegel RM.

Nat Rev Rheumatol. 2017 Apr;13(4):217-233. doi: 10.1038/nrrheum.2017.22. Epub 2017 Mar 9. Review.

PMID:
28275260
3.

Combination therapy with biologic agents in rheumatic diseases: current and future prospects.

Inui K, Koike T.

Ther Adv Musculoskelet Dis. 2016 Oct;8(5):192-202. Epub 2016 Aug 29. Review.

4.

Inhibition of Acute Lung Injury by TNFR-Fc through Regulation of an Inflammation-Oxidative Stress Pathway.

Weifeng Y, Li L, Yujie H, Weifeng L, Zhenhui G, Wenjie H.

PLoS One. 2016 Mar 18;11(3):e0151672. doi: 10.1371/journal.pone.0151672. eCollection 2016.

5.

TNF biology, pathogenic mechanisms and emerging therapeutic strategies.

Kalliolias GD, Ivashkiv LB.

Nat Rev Rheumatol. 2016 Jan;12(1):49-62. doi: 10.1038/nrrheum.2015.169. Epub 2015 Dec 10. Review.

6.

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.

Bootz F, Neri D.

Drug Discov Today. 2016 Jan;21(1):180-189. doi: 10.1016/j.drudis.2015.10.012. Epub 2015 Oct 23. Review.

7.

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, Schlereth B, Locher M, Bertschinger J, Grabulovski D.

MAbs. 2016;8(1):141-9. doi: 10.1080/19420862.2015.1093266. Epub 2015 Sep 22.

8.

Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade.

Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A, Itoh Y.

Arthritis Rheumatol. 2016 Feb;68(2):521-31. doi: 10.1002/art.39414.

9.

Treatment in juvenile rheumatoid arthritis and new treatment options.

Kasapçopur Ö, Barut K.

Turk Pediatri Ars. 2015 Mar 1;50(1):1-10. doi: 10.5152/tpa.2015.2229. eCollection 2015 Mar. Review.

10.

Evasion of inflammasome activation by microbial pathogens.

Ulland TK, Ferguson PJ, Sutterwala FS.

J Clin Invest. 2015 Feb;125(2):469-77. doi: 10.1172/JCI75254. Epub 2015 Feb 2. Review.

11.

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Román Ivorra JA, Poveda-Andrés JL, Muñoz-Fernández S; Spanish Rheumatology Society; Spanish Rheumatology Society.

Rheumatology (Oxford). 2015 Jul;54(7):1200-9. doi: 10.1093/rheumatology/keu461. Epub 2014 Dec 19.

12.

Anti-TNF therapy: past, present and future.

Monaco C, Nanchahal J, Taylor P, Feldmann M.

Int Immunol. 2015 Jan;27(1):55-62. doi: 10.1093/intimm/dxu102. Epub 2014 Nov 19. Review.

13.

Interleukin-1 receptor blockade in perinatal brain injury.

Rosenzweig JM, Lei J, Burd I.

Front Pediatr. 2014 Oct 7;2:108. doi: 10.3389/fped.2014.00108. eCollection 2014. Review.

14.

Restoring the balance: immunotherapeutic combinations for autoimmune disease.

Smilek DE, Ehlers MR, Nepom GT.

Dis Model Mech. 2014 May;7(5):503-13. doi: 10.1242/dmm.015099. Review.

15.

Effect of cytokines on osteoclast formation and bone resorption during mechanical force loading of the periodontal membrane.

Kitaura H, Kimura K, Ishida M, Sugisawa H, Kohara H, Yoshimatsu M, Takano-Yamamoto T.

ScientificWorldJournal. 2014 Jan 19;2014:617032. doi: 10.1155/2014/617032. eCollection 2014. Review.

16.

Emerging immunotherapies for rheumatoid arthritis.

Reynolds G, Cooles FA, Isaacs JD, Hilkens CM.

Hum Vaccin Immunother. 2014;10(4):822-37. Epub 2014 Feb 17. Review.

17.

Rituximab for the treatment of rheumatoid arthritis: an update.

Mok CC.

Drug Des Devel Ther. 2013 Dec 27;8:87-100. doi: 10.2147/DDDT.S41645. Review.

18.

Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.

Doll F, Schwager K, Hemmerle T, Neri D.

Arthritis Res Ther. 2013 Sep 27;15(5):R138. doi: 10.1186/ar4319.

19.

Caspase functions in cell death and disease.

McIlwain DR, Berger T, Mak TW.

Cold Spring Harb Perspect Biol. 2013 Apr 1;5(4):a008656. doi: 10.1101/cshperspect.a008656. Review. Erratum in: Cold Spring Harb Perspect Biol. 2015 Apr;7(4). pii: a026716. doi: 10.1101/cshperspect.a026716.

Supplemental Content

Support Center